

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer and its management and financial statements. The Company does not intend to make any public offering of securities in the United States.



维亚生物科技控股集团
VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

**FULL REDEMPTION OF
US\$180 MILLION 2.50 PER CENT GUARANTEED CONVERTIBLE
BONDS DUE 2025
(STOCK CODE: 40144)**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to the announcements of Viva Biotech Holdings (the “**Company**”) dated 23 January 2020, 5 February 2020, 11 February 2020, 16 February 2022 and 24 November 2022 (the “**Announcements**”) in relation to the 2.50 per cent guaranteed convertible bonds due 2025 issued by Viva Incubator Investment Management Limited (a wholly-owned subsidiary of the Company) (the “**Convertible Bonds**”). Unless otherwise stated, terms used in this announcement shall have the same meanings as defined in the Announcements.

The Company hereby announces that pursuant to the terms and conditions of the Convertible Bonds, the Bondholders holding an aggregate principal amount of US\$6,600,000 of the Convertible Bonds, representing approximately 3.7% of the aggregate principal amount of the Convertible Bonds originally issued, have exercised their option to require the Issuer to redeem all their Convertible Bonds on 11 February 2023 at 104.73% of the principal amount, together with interest accrued but unpaid to (but excluding) such date.

As of the date of this announcement, all Convertible Bonds have been redeemed and no Convertible Bonds remain outstanding. The Company has applied to The Stock Exchange of Hong Kong Limited for the withdrawal of the listing of the Convertible Bonds. Such withdrawal of listing is expected to become effective upon the close of business on 7 March 2023.

The Company considers that there will be no material impact on the financial position of the Company as a result of the aforesaid redemption of the Convertible Bonds.

By Order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

28 February 2023

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. WU Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. WU Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.